Clinical Trial Detail

NCT ID NCT03173950
Title Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

malignant glioma

gliosarcoma

pineoblastoma

choroid plexus papilloma

chordoma

brain stem glioma

meningioma

choroid plexus carcinoma

gliomatosis cerebri

atypical teratoid rhabdoid tumor

malignant ependymoma

brain sarcoma

medulloblastoma

Therapies

Nivolumab

Age Groups: adult senior

No variant requirements are available.